(Q54331057)

English

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

scientific article published on 14 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

J Salvador

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

L Manso

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J de la Haba

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

A Jaen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M C de Villena

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Gil

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

A Murias

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

A Galan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

C Jara

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J Bayo

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J M Baena

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J Casal

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J R Mel

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

I Blancas

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

P Sanchez Rvira

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

14 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

160-166

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25119930%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

https://scigraph.springernature.com/pub.10.1007/s12094-014-1210-x

0 references

Cancer treatment and survivorship statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS12094-014-1210-X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54331057&oldid=1561398700"